BioCentury
ARTICLE | Emerging Company Profile

Neo frontier

Why Gritstone thinks neoantigens are immuno-oncology's new frontier

November 9, 2015 8:00 AM UTC

Gritstone Oncology Inc. is developing personalized neoantigen-based vaccines that it expects to deliver to non-small cell lung cancer patients within a month of sequencing their tumors. To go from sequence to vaccine, the company will have to build its platform from scratch, answer a host of biological questions and select a method for delivering the antigens.

President and CEO Andrew Allen is charting an aggressive course to the clinic, thanks to a huge series A round that will enable the company to conduct multiple experiments in parallel. In October, Gritstone raised $102 million in a series A round, which Allen said should get the company through 2017. ...